The new offering will provide seamless access to Asimov’s CHO Edge cell line development platform, Cytiva's HyClone media and feed solutions, and Cytiva’s Fast Trak process development services.

Drusen is believed to damage RPE cells and contribute to their eventual loss and subsequent loss of photoreceptors. These data add to our growing understanding of zervimesine’s mechanism and its ...

Within the development set, 68 advanced-line patients were used as well ... CB, clinical benefit; ICI, immune checkpoint inhibitor; NSCLC, non–small cell lung cancer. From PROPHETIC, 500 patients with ...

He was a little coy on pricing, saying that it would be in line with other cell-based therapies that deliver long-term clinical benefits. The company is also developing MSC therapies for other ...

Validation of lymphocyte to monocyte ratio in resected small bowel adenocarcinoma as a predictor of survival. This is an ASCO Meeting Abstract from the 2019 ASCO Annual Meeting I. This abstract does ...

Monoclonal B-cell lymphocytosis is when your body produces an elevated number of identical B cells. In some cases, it can develop into chronic lymphocytic leukemia. Monoclonal B-cell lymphocytosis ...